Faculty Information |
|
Article types | Original article |
Language | English |
Refereed paper | Not refereed |
Title | Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial |
Journal | Formal name:Liver cancer Abbreviation:Liver Cancer ISSN code:2235179516645553 |
Domestic / Foregin | Foregin |
Volume, Number, Page | 8(6),pp.505-19 |
Papers・Author | Kudo Masatoshi, Ueshima Kazuomi, Chiba Yasutaka, Ogasawara Sadahisa, Obi Shuntaro, Izumi Namiki, Aikata Hiroshi, Nagano Hiroaki, Hatano Etsuro, Sasaki Yutaka, Hino Keisuke, Kumada Takashi, Yamamoto Kazuhide, Imai Yasuharu, Iwadou Shouta, Ogawa Chikara, Okusaka Takuji, Kanai Fumihiko, Arai Yasuaki |
Publication date | 2019/11 |
Papers・Description | Objective:In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between objective response by mRECIST and OS in the sorafenib group, in the combination group, and in all patients in the SILIUS trial.Methods:Association between objective response and OS in patients treated with sorafenib (nResults:In the sorafenib group, OS of responders (nConclusions:In the SILIUS trial, objective response by sorafenib assessed by mRECIST is an independent prognostic factor for OS in patients with HCC. |
DOI | 10.1159/000503032 |
PMID | 31799207 |